Frequency of KRAS G12C plus co-mutations in solid tumors and adequate test methods

被引：0

作者：

Schatz, Stefanie ^{[1
]}

Falk, Markus ^{[1
]}

Tiemann, Markus ^{[1
]}

机构：

[1] Inst Hamatopathol Hamburg, Hamburg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

554

引用

页码：176 / 176

页数：1

共 50 条

[41] Elucidating the mechanisms of acquired resistance to AMG510 in cancer models harboring KRAS G12C mutations
Ni, Ting
Huo, Tongxin
Zhang, Yawen
Wang, Jingjing
Liu, Gaoxiang
Shi, Wenting
Gu, Qingyang
CANCER RESEARCH, 2024, 84 (06)
[42] KRAS G12C Mutations Among NSCLC Patients Present With a High Intrerregional Variation, Indicating a Population Substructure
Ruiz-Patino, A.
Rodriguez, J. K.
Avila Coy, J.
Archila, P.
Cardona Zorrilla, A.
Sotelo, C.
Carranza, H.
Vargas, C.
Otero, J.
Bermudez, M.
Gamez, T.
Arrieta, O.
Zatarain Barron, L.
Rojas Puentes, L. L.
Corrales, L.
Martin, C.
Garcia-Robledo, J. E.
Santoyo Sarmiento, N. D.
Rolfo, C.
Rosell, R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1209 - S1209
[43] KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition
Patel, H.
Chan, S.
Smith, A.
Burrows, F.
Malik, S.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S146 - S146
[44] Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: Report of two cases
Siringo, M.
Larocca, F.
Spagnuolo, A.
Gentile, G.
Anile, M.
Diso, D.
Santini, D.
Gelibter, A.
CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2024, 14
[45] Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations
Burns, Timothy F.
Borghaei, Hossein
Ramalingam, Suresh S.
Mok, Tony S.
Peters, Solange
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (35) : 4208 - 4218
[46] KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
Koga, Takamasa
Suda, Kenichi
Fujino, Toshio
Ohara, Shuta
Hamada, Akira
Nishino, Masaya
Chiba, Masato
Shimoji, Masaki
Takemoto, Toshiki
Arita, Takeo
Gmachl, Michael
Hofmann, Marco H.
Soh, Junichi
Mitsudomi, Tetsuya
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (08) : 1321 - 1332
[47] Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours
Govindan, R.
Fakih, M. G.
Price, T. J.
Falchook, G. S.
Desai, J.
Kuo, J. C.
Strickler, J. H.
Krauss, J. C.
Li, B. T.
Denlinger, C. S.
Durm, G.
Ngang, J.
Henary, H.
Ngarmchamnanrith, G.
Rasmussen, E.
Morrow, P. K.
Hong, D. S.
ANNALS OF ONCOLOGY, 2019, 30 : 163 - +
[48] A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
Li, Jian
Zhao, Jun
Cao, Baoshan
Fang, Jian
Li, Xiaoyan
Wang, Mengzhao
Ba, Yi
Li, Xingya
Li, Zhihua
Liu, Zhe
Wang, Yongsheng
Cheng, Ying
Bai, Chunmei
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
Papadopoulos, Kyriakos P.
Ou, Sai-Hong Ignatius
Johnson, Melissa Lynne
Christensen, James
Velastegui, Karen
Potvin, Diane
Faltaos, Demiana
Chao, Richard C.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[50] Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors.
Li, Jian
Shen, Lin
Gu, Yanhong
Calles, Antonio
Wu, Lin
Ba, Yi
Li, Zhi-hua
Bai, Chunmei
Yao, Yu
Hubert, Ayala
Perez, Julia Martinez
Zugazagoitia, Jon
Ding, Yuli
Liu, Sumei
Rao, Zhiyue
He, Zhiwen
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 604 - 604

← 1 2 3 4 5 →